Products
Urtoxazumab Biosimilar Monoclonal Antibody (Shiga Toxin 2 B Subunit) for Research
Cat No.: GMP-Bios-INN-1040
Anti-E.coli Shiga-like toxin 2 B subunit therapeutic antibody (Pre-made Urtoxazumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.[1][2]
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1040-1mg | 1mg | 3090 |
| GMP-Bios-INN-1040-10mg | 10mg | |
| GMP-Bios-INN-1040-100mg | 100mg | |
| GMP-Bios-INN-1040-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Urtoxazumab Biosimilar, Whole Mab: Anti-E.Coli Shiga-Like Toxin 2 B Subunit therapeutic antibody |
| INN Name | Urtoxazumab |
| Target | E.coli Shiga-like toxin 2 B subunit |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Teijin Ltd. (Tokyo Japan) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
